New Pfizer partnership with Rexall Drugstore will help patients to stay on treatment
Patients who fill three or more chronic medications on a regular basis are eligible for the service and will enroll directly with their Rexall pharmacist. Following enrollment, in consultation with their pharmacist, a patient's medications will be synched so that they are refilled on a date that works best for them.
Pfizer Canada has partnered with Rexall in a new service called OneStopMeds to improve medication adherence and health outcomes for patients taking multiple chronic medications.
Low adherence to treatment is a significant issue in the Canadian healthcare system:
In fact, 6 months after being prescribed a specific treatment, 50% of patients do not adhere to it and this statistic has remained unchanged for the last 30 years. This issue is important since patients do not benefit from appropriate health outcomes and a partial course of treatment leads to inefficient use of already scarce healthcare resources.
The OneStopMeds partnership between Rexall and Pfizer aims to improve these numbers. Patients who fill three or more chronic medications on a regular basis are eligible for the service and will enroll directly with their Rexall pharmacist. Following enrollment, in consultation with their pharmacist, a patient's medications will be synched so that they are refilled on a date that works best for them. OneStopMeds reduces the number of trips to the pharmacy, ensures the patient has all of their medications and drives the pharmacist to engage and speak with their patients about their overall health and the medications they are taking.
''Pfizer is committed to working collaboratively with our pharmacy partners to demonstrate the value and role pharmacists play in the healthcare system'' said Gerry Stefanatos, General Manager, Global Established Products, Pfizer Canada. ''Partnerships such as OneStopMeds will improve medication adherence and ultimately patient care'' he added.
"Rexall and our pharmacists are leading the way when it comes to delivering patient focused services and the launch of OneStopMeds is another important step towards improving the health and wellness of Canadians," said Jürgen Schreiber, CEO of Rexall Health.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance